KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Operating Leases (2020 - 2025)

Vir Biotechnology's Operating Leases history spans 6 years, with the latest figure at $97.9 million for Q4 2025.

  • On a quarterly basis, Operating Leases changed 0.04% to $97.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $97.9 million, a 0.04% change, with the full-year FY2025 number at $97.9 million, changed 0.04% from a year prior.
  • Operating Leases hit $97.9 million in Q4 2025 for Vir Biotechnology, up from $91.2 million in the prior quarter.
  • Over the last five years, Operating Leases for VIR hit a ceiling of $133.6 million in Q4 2021 and a floor of $66.6 million in Q1 2021.
  • Historically, Operating Leases has averaged $105.0 million across 5 years, with a median of $103.5 million in 2024.
  • Biggest five-year swings in Operating Leases: soared 467.35% in 2021 and later dropped 21.4% in 2024.
  • Tracing VIR's Operating Leases over 5 years: stood at $133.6 million in 2021, then dropped by 4.18% to $128.0 million in 2022, then fell by 2.68% to $124.5 million in 2023, then fell by 21.4% to $97.9 million in 2024, then decreased by 0.04% to $97.9 million in 2025.
  • Business Quant data shows Operating Leases for VIR at $97.9 million in Q4 2025, $91.2 million in Q3 2025, and $93.4 million in Q2 2025.